137 related articles for article (PubMed ID: 34931733)
1. The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes.
Johansson U; McIver-Brown N; Cullen M; Duetz C; Dunlop A; Oelschlägel U; Psarra K; Subirá D; Westers TM
Cytometry B Clin Cytom; 2023 Mar; 104(2):115-127. PubMed ID: 34931733
[TBL] [Abstract][Full Text] [Related]
2. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
Font P; Subirá D; Matarraz S; Benavente C; Cedena MT; Morado M; Pérez Corral A; Bellón JM; Díez-Martín JL
Cytometry B Clin Cytom; 2018 May; 94(3):527-535. PubMed ID: 28618451
[TBL] [Abstract][Full Text] [Related]
3. Clinical, immunophenotypic, and cytogenetic characteristics of high-grade myelodysplastic syndromes with CD41-positive progenitor cells.
Ogata K; Sei K; Kawahara N; Ogata M; Yamamoto Y
Cytometry B Clin Cytom; 2023 Jan; 104(1):98-107. PubMed ID: 34964228
[TBL] [Abstract][Full Text] [Related]
4. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Leukemia; 2016 Mar; 30(3):658-65. PubMed ID: 26503643
[TBL] [Abstract][Full Text] [Related]
5. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
6. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
[TBL] [Abstract][Full Text] [Related]
7. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
[TBL] [Abstract][Full Text] [Related]
8. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
[TBL] [Abstract][Full Text] [Related]
9. Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes.
Shameli A; Dharmani-Khan P; Auer I; Shabani-Rad MT
Leuk Res; 2023 Nov; 134():107401. PubMed ID: 37774446
[TBL] [Abstract][Full Text] [Related]
10. Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.
Behbehani GK; Finck R; Samusik N; Sridhar K; Fantl WJ; Greenberg PL; Nolan GP
Cytometry B Clin Cytom; 2020 Mar; 98(2):131-145. PubMed ID: 31917512
[TBL] [Abstract][Full Text] [Related]
11. Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.
Alhan C; Westers TM; Cremers EM; Cali C; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2016 Jul; 90(4):358-67. PubMed ID: 26517178
[TBL] [Abstract][Full Text] [Related]
12. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.
Verigou E; Lampropoulou P; Smyrni N; Kolliopoulou G; Sakellaropoulos G; Starakis I; Zikos P; Solomou E; Symeonidis A; Karakantza M
Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):148-61. PubMed ID: 26126819
[TBL] [Abstract][Full Text] [Related]
14. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
[TBL] [Abstract][Full Text] [Related]
15. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes.
Molteni A; Riva M; Cesana C; Speziale V; Nichelatti M; Scarpati B; Greco R; Ravano E; Cairoli R; Rossini S; Morra E
Eur J Haematol; 2015 Jun; 94(6):519-25. PubMed ID: 25307971
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of myeloid nuclear differentiation antigen distinguishes myelodysplastic syndrome from normal bone marrow.
McClintock-Treep SA; Briggs RC; Shults KE; Flye-Blakemore LA; Mosse CA; Jagasia MH; Shinar AA; Dupont WD; Stelzer GT; Head DR
Am J Clin Pathol; 2011 Mar; 135(3):380-5. PubMed ID: 21350091
[TBL] [Abstract][Full Text] [Related]
18. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS.
Westers TM; van der Velden VH; Alhan C; Bekkema R; Bijkerk A; Brooimans RA; Cali C; Dräger AM; de Haas V; Homburg C; de Jong A; Kuiper-Kramer PE; Leenders M; Lommerse I; te Marvelde JG; van der Molen-Sinke JK; Moshaver B; Mulder AB; Preijers FW; Schindhelm RK; van der Sluijs A; van Wering ER; Westra AH; van de Loosdrecht AA;
Leuk Res; 2012 Apr; 36(4):422-30. PubMed ID: 21982641
[TBL] [Abstract][Full Text] [Related]
19. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.
Westers TM; Ireland R; Kern W; Alhan C; Balleisen JS; Bettelheim P; Burbury K; Cullen M; Cutler JA; Della Porta MG; Dräger AM; Feuillard J; Font P; Germing U; Haase D; Johansson U; Kordasti S; Loken MR; Malcovati L; te Marvelde JG; Matarraz S; Milne T; Moshaver B; Mufti GJ; Ogata K; Orfao A; Porwit A; Psarra K; Richards SJ; Subirá D; Tindell V; Vallespi T; Valent P; van der Velden VH; de Witte TM; Wells DA; Zettl F; Béné MC; van de Loosdrecht AA
Leukemia; 2012 Jul; 26(7):1730-41. PubMed ID: 22307178
[TBL] [Abstract][Full Text] [Related]
20. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
